/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. The Uromigos
  2. Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates
Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates

The Uromigos · Aug 31, 2026

Experts discuss HIF inhibitors in RCC, highlighting Casdatifan's clinical data, distinct biomarkers, and its potential differentiation from Belzutafan.

Casdatifan Responds in Tumors with High EMT Signatures, Contradicting Its Expected Efficacy in Earlier-Stage Disease

HIF inhibitors were expected to work best in less aggressive tumors. However, data shows Casdatifan response correlates with high Epithelial-Mesenchymal Transition (EMT) signatures, which are typically associated with aggressive biology. This paradox suggests EMT is more complex than just a marker of aggression and may indicate a specific vulnerability.

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates thumbnail

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates

The Uromigos·3 months ago

Intensive Biomarker Research in Phase 1 De-Risks Later Stage Drug Development

The extensive translational and biomarker work published in Nature from a Phase 1 study of Casdatifan is a model for modern drug development. Understanding the drug's mechanism, pharmacodynamics, and response signatures from day one provides a 'backup plan' and helps avoid costly Phase 3 failures.

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates thumbnail

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates

The Uromigos·3 months ago

HIF Inhibitors Succeed in Adjuvant Kidney Cancer Trials Where VEGF TKIs Failed, Proving Distinct Mechanisms

Despite both targeting angiogenesis, HIF inhibitors like belzutafan show different clinical activity. Belzutafan's success in an adjuvant trial, a setting where multiple VEGF TKIs failed, alongside its additive effect in combination therapies, demonstrates it engages a separate biological pathway.

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates thumbnail

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates

The Uromigos·3 months ago

Oncology Trials Can Be 'Negative Positive Studies' When Statistical Wins Don't Translate to Meaningful Clinical Benefit

The COSMIC-313 trial is cited as a 'negative positive study' because it met its primary endpoint, but the overall results for response and survival were underwhelming, especially given the toxicity. This highlights a critical trap in drug development: a statistically significant result is not always clinically meaningful.

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates thumbnail

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates

The Uromigos·3 months ago

Failed Triplet Cancer Therapies May Be Due to Toxicity Preventing Drug Delivery, Not Lack of Efficacy

The negative result of a first-line triplet trial including belzutafan might not indicate the drug is ineffective in earlier disease. Instead, the combination's toxicity could have prevented patients from receiving an adequate dose for a sufficient duration, masking the drug's true potential. This distinguishes a mechanism failure from a combination toxicity failure.

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates thumbnail

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates

The Uromigos·3 months ago

A Key Goal for HIF Inhibitor Biomarkers Is Identifying Patients Who Can Thrive on Well-Tolerated Monotherapy

The most satisfying clinical outcomes are often patients on well-tolerated HIF inhibitor monotherapy who achieve long-term disease control. A robust biomarker's value is not just predicting response to combinations, but identifying the specific subset of patients who can avoid more toxic regimens entirely.

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates thumbnail

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates

The Uromigos·3 months ago

Using Erythropoietin in HIF-Treated Cancer Patients is Safe and Improves Outcomes by Enabling Longer Therapy Duration

Despite theoretical concerns that erythropoietin (a growth factor) could be dangerous in cancer, clinical data shows patients treated with it have better progression-free survival. The benefit comes from managing anemia, which allows patients to stay on the effective HIF inhibitor therapy longer, outweighing any hypothetical risks.

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates thumbnail

Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates

The Uromigos·3 months ago